2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Heuser, Michael; Freeman, Sylvie; J. Ossenkoppele, Gert; Buccisano, Francesco; S. Hourigan, Christopher; Lam Ngai, Lok; M. Tettero, Jesse; Bachas, Costa; Baer, Constance; C. Béné, Marie; Bücklein, Veit; Czyż, Anna; Denys, Barbara; Dillon, Richard; Feuring‐Buske, Michaela; L. Guzmán, Mónica; Haferlach, Torsten; Han, Lina; Herzig, Julia; L. Jorgensen, Jeffrey; Kern, Wolfgang; Konopleva, Marina; Lacombe, Francis; Libura, Marta; Majchrzak, Agata; Maurillo, Luca; Ofran, Yishai; Philippé, Jan; Pleșa, Adriana; Preudhomme, Claude; Ravandi, Farhad; Roumier, Christophe; Subklewe, Marion; Thol, Felicitas; A. van de Loosdrecht, Arjan; A. van der Reijden, Bert; Venditti, Adriano; Wierzbowska, Agnieszka; J.M. Valk, Peter; L. Wood, Brent; B. Walter, Roland; Thiede, Christian; Döhner, Konstanze; J. Roboz, Gail; Cloos, Jacqueline

doi:10.1182/blood.2021013626

Public

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Published in Blood • Nov 1, 2021

Authors:

Michael Heuser

Sylvie Freeman

Gert J. Ossenkoppele

Abstract

Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party evaluated standardization and harmonization of MRD in an ongoing manner...

Subject

Medicine

Minimal residual disease

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!